Interestingly, they showed that the EP1 groups had similar tumor regression response to EP2 groups, however, EP1 groups showed higher immune cell infiltrate (CD11b positive cells), higher tumor rejection upon rechallenge and longer long-term survival compared to EP2 higher level expression groups, signaling the role of IL-12 in generating or abrogating an adequate immune response depends on its level and possibly duration of expression. The gene discussed is ITGAM; the disease is neoplasm.